Celltrion DiaTrust™ Covid-19 Ag Rapid Test

Description

Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid and receptor binding domain (RBD) antigens in direct mid-turbinate nasal swab specimens. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigens.

Results in 15 minutes.

Includes:

25 test devices
25 swabs
25 extraction buffer
25 filter caps
1 positive control swab
1 negative control swab
1 Quick Reference Instruction

Quick Reference Instructions

Instructions for Use

Fact Sheet for Patients

Fact Sheet for Healthcare Providers

FDA EUA Letter

PRECAUTIONS AND WARNINGS

• For use under Emergency Use Authorization Only.
• For in vitro diagnostic use only.
• For prescription use only.
• Read all instructions completely and carefully before performing the test. Failure to follow all instructions may result in inaccurate test results.
• In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories certified under the CLIA that meet the requirements to perform high or moderate complexity, or waived tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.
• Serial testing should be performed in individuals with negative results at least twice over three days (with 48 hours between tests) for symptomatic individuals and three times over five days (with at least 48 hours between tests) for asymptomatic individuals. You may need to purchase additional tests to perform this serial (repeat) testing.
• If the individual has had symptoms longer than 7 days you should consider testing them at least three times over five days with at least 48 hours between tests.
• Use appropriate precautions in the collection, handling and storage of patient samples. Refer to CDC Interim Guidelines for Collection, Handling and Transportation of clinical specimens from persons with Coronavirus Disease 2019 (COVID-19) at https://www.cdc.gov/coronavirus/2019- nCoV/lab/guidelines-clinical-specimens.html, and to WHO’s Interim guidance for Laboratory testing for coronavirus disease (COVID-19) in suspected human cases at http://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-insuspected-human-cases-20200117, as amended and supplemented. Refer to the WHO website for additional publications.
• Federal Law restricts this device to sale by or on the order of a licensed practitioner (US only).
• Laboratories within the United States and its territories are required to report all results to the appropriate public health laboratories.
• Do not use kit past its expiration date.
• Keep sealed until usage, and once opened use immediately.
• Do not use if any of the test kit contents or packaging is damaged.
• Do not use the test device if the pouch is damaged or the device is seriously broken.
• Test components are single-use. Do not re-use.
• Do not touch the swab tip.
• Handle all specimens safely as potentially infectious.
• Once opened, the test card should be used within 1 hour.
• Do not read test results before 15 minutes or after 20 minutes. Results read before 15 minutes or after 20 minutes may lead to a false positive, false negative, or invalid result.
• All samples, even after the extraction procedure, and reagents containing biological materials used for the assay must be considered as potentially able to transmit infectious agents; accordingly samples, reagents and the waste must be handled with utmost care and disposed of in compliance with the laboratory guidelines and the statutory provisions in force in each country.
• This test is intended for assessment of coronavirus infection by detecting COVID-19 antigen, but should not be used as a sole criterion for the determination of SARS-CoV-2 infection. Other methods and clinical information (signs and symptoms) should be used and considered for diagnosis.
• Discard Celltrion DiaTrust™ COVID-19 Ag Rapid Test in accordance with local, state and federal regulations or accreditation requirements For more information on EUAs please visit: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policyframework/emergency-use-authorization
• For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19